Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Bristol Myers Squibb raised its 2026 revenue forecast to $49.75B-$50.25B but lowered EPS guidance to $6.35-$6.55 due to acquisition-related charges. Q3 revenue grew 7% to $13.1B, beating estimates, with strong sales of newer drugs like Breyanzi and Reblozyl. Shares rose 2.3% premarket.
How this was made
The 30-second read
Why it matters
The guidance update changes the earnings model immediately: revenue expectations rise, but EPS falls due to a disclosed acquisition-related charge. The article also adds near-term operating context via Q3 beats and product-level trends (Breyanzi, Reblozyl, Opdivo, Qvantig, Eliquis).
Market read
Traders can reprice BMY’s 2026 earnings trajectory using the new revenue and EPS ranges, with the EPS drag explicitly tied to an acquisition-related charge.
What to watch
Clinical-trial resumption timing for zolacabtagene autoleucel in autoimmune diseases (early 2027) and ongoing safety review dynamics could drive future sentiment beyond the guidance numbers.
Background
Bristol Myers is updating full-year 2026 guidance alongside ongoing pipeline and clinical-trial safety review work, including a pause and FDA discussions for an experimental cell therapy.
Ticker impact
Bristol Myers raised 2026 revenue guidance to $49.75B-$50.25B but cut 2026 EPS to $6.35-$6.55 due to a 60-cent acquisition-related charge.
Shares may face near-term EPS pressure as the market prices the acquisition-related charge, while revenue upside from newer drugs provides support.
The article provides explicit direction on both revenue and EPS, with the EPS reduction attributed to a specific charge and revenue increase attributed to stronger sales of newer medicines.
Market effects
Signals continued commercial momentum in newer oncology and anemia franchises, but highlights earnings volatility from acquisition-related charges in large pharma.
US large-cap pharma sentiment may tilt toward revenue resilience despite EPS noise.
Limited direct global spillover beyond read-through to pharma guidance quality and pipeline execution risk.
Counterpoint
The EPS cut may be largely non-operational (one-time charge), so investors could refocus on revenue growth and pipeline progress rather than earnings quality.
Key entities
- companyBristol Myers Squibb
Raised 2026 revenue forecast but lowered 2026 EPS due to a 60-cent acquisition-related charge; reported Q3 revenue and adjusted EPS beats and discussed FDA trial enrollment plans.
- regulatorFDA
Working with Bristol Myers to resume enrollment in autoimmune-disease trials for zolacabtagene autoleucel in early 2027.
- companyNovartis
Halted eight clinical trials of an experimental cell therapy after three patient deaths, prompting Bristol Myers to pause its own studies for safety review.
